Beneficial effect of tacrolimus on myasthenia gravis with thymoma

Neurologist

Volumn 13, Issue 2, 2007, Pages 83-86

  Mitsui, Takao ^a,b   Kunishige, Makoto ^a   Ichimiya, Michiko ^a   Shichijo, Kana ^a   Endo, Itsuro ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Myasthenia gravis; Tacrolimus; Thymectomy; Thymoma

Indexed keywords

AMBENONIUM; AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CISPLATIN; DOXORUBICIN; PREDNISOLONE; TACROLIMUS; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FAILURE; MALE; MYASTHENIA GRAVIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM; THYMECTOMY; THYMOMA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNITY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, NICOTINIC; TACROLIMUS; THYMOMA; TREATMENT OUTCOME;

EID: 33947152488     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000256352.77668.ef     Document Type: Article

References (20)

1. Vincent A, Drachman DB. Myasthenia gravis. In: Pourmand R, Harati Y, eds. Neuromuscular Disorders. Philadelphia: Lippincott Williams & Wilkins; 2001:159-188.
2. Lewis RA, Selwa JF, Lisak RP. Myasthenia gravis: immunological mechanisms and immunotherapy. Ann Neurol. 1995;37:S51-S62.
3. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357:2122-2128.
4. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;55:7-15.
5. Buckley C, Douek D, Newsom-Davis J, et al. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol. 2001;50:64-72.
6. Reinhardt C, Melms A. Normalization of elevated CD4+/CD8+ (double-negative) T cells after thymectomy parallels clinical remission in myasthenia gravis associated with thymic hyperplasia but not thymoma. Ann Neurol. 2000;48:603-608.
7. Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry. 1998;64:78-83.
8. Bierer BE, Holländer G, Fruman D, et al. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol. 1993;5:763-773.
9. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000;47:63-83.
10. Konishi T, Yoshiyama Y, Takamori M, et al. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry. 2005;76:448-450.
11. Tada M, Shimohata T, Tada M, et al. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci. 2006;247:17-20.
12. Jaretzki III A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55:16-23.
13. Tindall RSA, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316:719-724.
14. Hoffacker V, Schultz A, Tiesinga JJ, et al. Thymomas alter the T cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000;96:3872-3879.
15. Namba T, Brunner NG, Grob D. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine. 1978;57:411-433.
16. Evoli A, Di Schino C, Marsili F, et al. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve. 2002;25:111-114.
17. Utsugisawa K, Nagane Y, Yonezawa H, et al. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle Nerve. 2003;27:245-248.
18. Zhang G-X, Navikas V, Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve. 1997;20:543-551.
19. Yoshikawa H, Satoh K, Yasukawa Y, et al. Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis. J Clin Neurosci. 2002;9:133-136.
20. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathological study of 200 thymoma cases from China. Cancer. 2002;95:420-429.